New insights into oxidative stress and immune mechanisms involved in age-related macular degeneration tackled by novel therapies

dc.creatorPotilinski, María Constanza
dc.creatorTate, Pablo Sebastián
dc.creatorLorenc, Valeria Erika
dc.creatorGallo, Juan Eduardo Maria
dc.date2021-05
dc.date.accessioned2023-08-30T23:45:53Z
dc.date.available2023-08-30T23:45:53Z
dc.identifierhttp://hdl.handle.net/11336/184247
dc.identifierPotilinski, María Constanza; Tate, Pablo Sebastián; Lorenc, Valeria Erika; Gallo, Juan Eduardo Maria; New insights into oxidative stress and immune mechanisms involved in age-related macular degeneration tackled by novel therapies; Pergamon-Elsevier Science Ltd; Neuropharmacology; 188; 5-2021; 1-13
dc.identifier0028-3908
dc.identifierCONICET Digital
dc.identifierCONICET
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/8542754
dc.descriptionThe prevalence of age-related macular degeneration (AMD) has increased in the last years. Although anti-VEGF agents have improved the prognosis of exudative AMD, dry AMD has still devastating effects on elderly people vision. Oxidative stress and inflammation are mechanisms involved in AMD pathogenesis and its progression. Molecular pathways involving epidermal growth factor receptor (EGFR), bone morphogenetic protein (BMP4) and the nuclear erythroid related factor 2 (Nrf2) are behind oxidative stress in AMD due to their participation in antioxidant cellular pathways. As a consequence of the disbalance produced in the antioxidant mechanisms, there is an activation of innate and adaptative immune response with cell recruitment, changes in complement factors expression, and modification of cellular milieu. Different therapies are being studied to treat dry AMD based on the possible effects on antioxidant molecular pathways or their action on the immune response. There is a wide range of treatments presented in this review, from natural antioxidant compounds to cell and gene therapy, based on their mechanisms. Finally, we hypothesize that alpha-1-antitrypsin (AAT), an anti-inflammatory and immunomodulatory molecule that can also modulate antioxidant cellular defenses, could be a good candidate for testing in AMD.
dc.descriptionFil: Potilinski, María Constanza. Universidad Austral. Facultad de Ciencias Biomédicas. Instituto de Investigaciones en Medicina Traslacional. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. Instituto de Investigaciones en Medicina Traslacional; Argentina
dc.descriptionFil: Tate, Pablo Sebastián. Universidad Austral. Facultad de Ciencias Biomédicas. Instituto de Investigaciones en Medicina Traslacional. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. Instituto de Investigaciones en Medicina Traslacional; Argentina
dc.descriptionFil: Lorenc, Valeria Erika. Universidad Austral. Facultad de Ciencias Biomédicas. Instituto de Investigaciones en Medicina Traslacional. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. Instituto de Investigaciones en Medicina Traslacional; Argentina
dc.descriptionFil: Gallo, Juan Eduardo Maria. Universidad Austral. Facultad de Ciencias Biomédicas. Instituto de Investigaciones en Medicina Traslacional. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. Instituto de Investigaciones en Medicina Traslacional; Argentina
dc.formatapplication/pdf
dc.formatapplication/pdf
dc.formatapplication/pdf
dc.languageeng
dc.publisherPergamon-Elsevier Science Ltd
dc.relationinfo:eu-repo/semantics/altIdentifier/url/https://linkinghub.elsevier.com/retrieve/pii/S0028390821000678
dc.relationinfo:eu-repo/semantics/altIdentifier/doi/10.1016/j.neuropharm.2021.108513
dc.rightsinfo:eu-repo/semantics/restrictedAccess
dc.rightshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.subjectADAPTATIVE IMMUNITY
dc.subjectAGE-RELATED MACULAR DEGENERATION
dc.subjectALPHA-1 ANTITRYPSIN
dc.subjectINNATE IMMUNITY
dc.subjectOXIDATIVE STRESS
dc.subjectSIGNALING
dc.subjecthttps://purl.org/becyt/ford/3.1
dc.subjecthttps://purl.org/becyt/ford/3
dc.subjecthttps://purl.org/becyt/ford/3.2
dc.subjecthttps://purl.org/becyt/ford/3
dc.titleNew insights into oxidative stress and immune mechanisms involved in age-related macular degeneration tackled by novel therapies
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:ar-repo/semantics/artículo
dc.typeinfo:eu-repo/semantics/publishedVersion


Este ítem pertenece a la siguiente institución